SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Audentes Therapeutics, Inc. to Astellas Pharma Inc. is Fair to Shareholders
NEW YORK, NY / ACCESSWIRE / December 4, 2019 / The following statement is being issued by Levi & Korsinsky, LLP:
To: All Persons or Entities who purchased Audentes Therapeutics, Inc. ("Audentes" or the "Company") (NASDAQ:BOLD) stock prior to December 2, 2019.
You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Audentes to Astellas Pharma Inc. ("Astellas"). Under the terms of the transaction, Astellas will acquire Audentes at a price of $60.00 per share in cash. To learn more about the action and your rights, go to:
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500. There is no cost or obligation to you.
The investigation of Audentes merger concerns whether the Board of Audentes breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction and whether Astellas is underpaying for Audentes shares, thus unlawfully harming Audentes shareholders.
Levi & Korsinsky is a national firm with offices in New York, Connecticut, California, and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
Tel: (212) 363-7500
Fax: (212) 363-7171
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com: